ADZENYS XR-ODT (amphetamine extended-release) by Therapeutic Solutions International is non-catecholamine sympathomimetic amines with cns stimulant activity. Approved for attention deficit hyperactivity disorder (adhd) in patients 6 years, older [see clinical studies ( )], older. First approved in 2016.
Drug data last refreshed 4h ago · AI intelligence enriched 3w ago
ADZENYS XR-ODT is an extended-release, orally disintegrating tablet formulation of amphetamine indicated for ADHD in patients 6 years and older. It is a CNS stimulant that blocks the reuptake of norepinephrine and dopamine, increasing their release into the extraneuronal space. The mechanism of therapeutic action in ADHD is not fully understood.
At peak lifecycle with minimal Part D utilization ($1M, 1,972 claims in 2023), indicating niche market positioning with limited team expansion opportunity.
non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal…
Central Nervous System Stimulant
Worked on ADZENYS XR-ODT at Therapeutic Solutions International? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moADZENYS XR-ODT currently has zero linked job openings, reflecting its niche market position and modest commercial footprint. Roles on this product focus on maintaining market share and managing safety signals rather than scaling new infrastructure.